[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA02003321A - Composiciones de liberacion controlada que comprenden nimesulida. - Google Patents

Composiciones de liberacion controlada que comprenden nimesulida.

Info

Publication number
MXPA02003321A
MXPA02003321A MXPA02003321A MXPA02003321A MXPA02003321A MX PA02003321 A MXPA02003321 A MX PA02003321A MX PA02003321 A MXPA02003321 A MX PA02003321A MX PA02003321 A MXPA02003321 A MX PA02003321A MX PA02003321 A MXPA02003321 A MX PA02003321A
Authority
MX
Mexico
Prior art keywords
nimesulide
controlled release
release compositions
dosage form
oral dosage
Prior art date
Application number
MXPA02003321A
Other languages
English (en)
Inventor
Singh Amarjit
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MXPA02003321A publication Critical patent/MXPA02003321A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a una composicion farmaceutica de liberacion controlada de nimesulida que comprende la nimesulida como un farmaco activo, uno o mas materiales de sostenimiento y excipientes farmaceuticos formulados en una forma farmaceutica oral de una vez por dia de liberacion controlada.
MXPA02003321A 1999-09-28 2000-09-27 Composiciones de liberacion controlada que comprenden nimesulida. MXPA02003321A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1297DE1999 1999-09-28
PCT/IN2000/000094 WO2001022791A2 (en) 1999-09-28 2000-09-27 Controlled release compositions comprising nimesulide

Publications (1)

Publication Number Publication Date
MXPA02003321A true MXPA02003321A (es) 2004-09-10

Family

ID=11092667

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003321A MXPA02003321A (es) 1999-09-28 2000-09-27 Composiciones de liberacion controlada que comprenden nimesulida.

Country Status (26)

Country Link
US (2) US20070128276A1 (es)
EP (1) EP1218889B1 (es)
JP (2) JP4359412B2 (es)
KR (1) KR100621281B1 (es)
CN (2) CN1399543A (es)
AP (1) AP1954A (es)
AT (1) ATE450865T1 (es)
AU (1) AU774099B2 (es)
BG (1) BG66093B1 (es)
BR (1) BR0014383A (es)
CA (1) CA2385890C (es)
CZ (1) CZ20021076A3 (es)
DE (1) DE60043447D1 (es)
DK (1) DK1218889T3 (es)
ES (1) ES2337547T3 (es)
HU (1) HUP0204451A3 (es)
IL (2) IL148864A0 (es)
MX (1) MXPA02003321A (es)
NO (1) NO20021540L (es)
NZ (1) NZ518052A (es)
PT (1) PT1218889E (es)
RS (1) RS50303B (es)
RU (1) RU2238087C2 (es)
UA (1) UA80667C2 (es)
WO (1) WO2001022791A2 (es)
ZA (1) ZA200202411B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522079A (ja) * 2003-10-31 2007-08-09 エラン ファーマ インターナショナル リミテッド ニメスリド組成物
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
EP1906933A2 (en) * 2005-07-20 2008-04-09 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
CN100346778C (zh) * 2005-07-22 2007-11-07 海南康力元药业有限公司 尼美舒利缓释组合物
US20090258947A1 (en) * 2006-04-24 2009-10-15 Rajesh Jain Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
BE1018280A3 (fr) * 2008-09-09 2010-08-03 Squarepoint Pointcarre Sprl Composition de nimesulide a liberation prolongee.
BRPI0919010A2 (pt) 2008-09-22 2015-08-18 Rubicon Res Private Ltd Composições exibindo trânsito retardado através do trato gastrointestinal.
WO2010100657A2 (en) * 2009-03-04 2010-09-10 Fdc Limited A novel oral controlled release dosage forms for water soluble drugs
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CN102188386B (zh) * 2010-03-02 2013-09-04 海南葫芦娃制药有限公司 尼美舒利缓释微丸及其制备方法
CN102232928A (zh) * 2010-04-20 2011-11-09 广州艾格生物科技有限公司 一种尼美舒利缓释干混悬剂及其制备方法
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN102485220A (zh) * 2010-12-03 2012-06-06 沈阳药科大学 尼美舒利单层渗透泵控释片
WO2012159077A2 (en) * 2011-05-18 2012-11-22 Board Of Regents, The University Of Texas System Multiple dosing regimen oral drug delivery platform
CN103142565B (zh) * 2012-04-18 2015-04-29 中国人民解放军军事医学科学院毒物药物研究所 一种尼美舒利的缓释药物组合物及其制备方法
SG11201606689VA (en) 2014-02-13 2016-09-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
MY196877A (en) 2014-02-13 2023-05-08 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN105435239B (zh) * 2014-08-29 2019-04-26 武汉光谷人福生物医药有限公司 美索舒利薄膜衣片及其制备方法
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
RU2017141029A (ru) * 2015-05-25 2019-06-25 Сан Фармасьютикал Индастриз Лимитед Фармацевтическая пероральная композиция изотретиноина для применения один раз в сутки
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
WO2018190621A1 (ko) * 2017-04-10 2018-10-18 성균관대학교 산학협력단 다공성 위체류층을 포함하는 서방성 제제 및 이의 제조방법
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4666928A (en) * 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
IN187379B (es) * 1996-04-12 2002-04-13 Panacea Biotec Ltd
EP0906106B1 (en) * 1996-05-23 2008-05-07 Novartis AG Prevention and treatment of colonic adenoma or colonic microadenoma by 6-fluoroursodeoxycholic acid (6-fudca)
IN186315B (es) * 1996-12-12 2001-08-04 Panacea Biotec Ltd
ES2129010B1 (es) * 1997-01-02 2000-01-16 Gold Oscar Composicion de accion prolongada en granulos que contienen 4-nitro-2- fenoximetansulfonanilida y su procedimiento de preparacion.
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
CA2301883A1 (en) * 1997-09-11 1999-03-18 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
IN188720B (es) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória

Also Published As

Publication number Publication date
CN1399543A (zh) 2003-02-26
JP2003534236A (ja) 2003-11-18
UA80667C2 (en) 2007-10-25
EP1218889A2 (en) 2002-07-03
AU2879901A (en) 2001-04-30
DE60043447D1 (de) 2010-01-14
IL148864A0 (en) 2002-09-12
BG106605A (bg) 2002-12-29
JP4359412B2 (ja) 2009-11-04
RU2002111365A (ru) 2004-01-27
HUP0204451A2 (hu) 2003-06-28
IL148864A (en) 2008-06-05
WO2001022791A2 (en) 2001-04-05
KR20020097138A (ko) 2002-12-31
PL358369A1 (en) 2004-08-09
US20080160082A1 (en) 2008-07-03
BG66093B1 (bg) 2011-04-29
PT1218889E (pt) 2010-03-08
DK1218889T3 (da) 2010-04-12
RS50303B (sr) 2009-09-08
NO20021540D0 (no) 2002-03-27
NZ518052A (en) 2005-04-29
HUP0204451A3 (en) 2004-05-28
CN101804041A (zh) 2010-08-18
ES2337547T3 (es) 2010-04-27
US20070128276A1 (en) 2007-06-07
ATE450865T1 (de) 2009-12-15
NO20021540L (no) 2002-05-28
WO2001022791A8 (en) 2002-10-31
ZA200202411B (en) 2003-06-26
WO2001022791A3 (en) 2002-01-31
JP2007217436A (ja) 2007-08-30
CZ20021076A3 (cs) 2002-08-14
RU2238087C2 (ru) 2004-10-20
EP1218889B1 (en) 2009-12-02
AP1954A (en) 2009-02-10
AU774099B2 (en) 2004-06-17
CA2385890C (en) 2007-04-03
YU23402A (sh) 2004-12-31
BR0014383A (pt) 2002-10-22
CA2385890A1 (en) 2001-04-05
KR100621281B1 (ko) 2006-09-13

Similar Documents

Publication Publication Date Title
AP1954A (en) Controlled release compositions comprising nimesulide.
PL348734A1 (en) New sustained release oral formulations
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
EE9900288A (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
IL153297A0 (en) Compounds and compositions for delivering active agents
BR9810495A (pt) Composição farmacêutica
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
ECSP083351A (es) Composiciones farmacéuticas
TW200503775A (en) Pharmaceutical composition and method for treating
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
AP2003002763A0 (en) Controlled release formulations for oral administration
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
WO2005065639A3 (en) Novel pharmaceutical compositions
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
MY145885A (en) Controlled release formulations for oral administration
DE50311479D1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung

Legal Events

Date Code Title Description
FG Grant or registration